



Taylor, S., Spada, E., Callan, M. B., Korman, R., Leister, E., Steagall, P., Lobetti, R., Seth, M., & Tasker, S. (2021). 2021 ISFM Consensus Guidelines on the Collection and Administration of Blood and Blood Products in Cats. *Journal of Feline Medicine and Surgery*, 23(5), 410-432. <https://doi.org/10.1177/1098612X211007071>

Peer reviewed version

Link to published version (if available):  
[10.1177/1098612X211007071](https://doi.org/10.1177/1098612X211007071)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via SAGE Publications at <https://journals.sagepub.com/doi/10.1177/1098612X211007071> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **International Society of Feline Medicine Consensus Guidelines on the collection and**  
2 **administration of blood and blood products in cats**

3 Samantha Taylor<sup>1</sup>, Eva Spada<sup>2</sup>, Mary Beth Callan<sup>3</sup>, Rachel Korman<sup>4</sup>, Ellie Lister<sup>5</sup>, Paulo Steagall<sup>6</sup>, Remo  
4 Lobetti<sup>7</sup>, Mayank Seth<sup>8</sup>, Séverine Tasker<sup>9,10</sup>

5 1 International Society of Feline Medicine, Tisbury, UK\* Corresponding author

6 2 Veterinary Transfusion Research Laboratory (REVLab), Department of Veterinary Medicine  
7 (DIMEVET), University of Milan, Lodi, Italy; ORCID no. 0000-0003-3898-6955

8 3 Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University  
9 of Pennsylvania, Philadelphia, Pennsylvania, USA

10 4 Cat Specialist Services, Underwood, Queensland, AUSTRALIA

11 5 TBC

12 6 Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal. 3200 rue  
13 Sicotte, Saint-Hyacinthe, QC, J2S 2M2, Canada.

14 7 Bryanston Veterinary Hospital, Johannesburg, South Africa

15 8 Dick White Referrals, Six Mile Bottom, UK

16 9 Bristol Veterinary School, University of Bristol, Langford, UK; ORCID no 0000-0002-4059-1402

17 10 Linnaeus Group, Shirley, B90 4BN

18 **Abstract**

19 **Practical relevance:** Blood and blood products are increasingly available for practitioners to use in  
20 the management of haematological conditions and can be lifesaving and therapeutically useful for  
21 patients with anaemia and/or coagulopathies. It is important for feline health care that donors are  
22 selected appropriately, and transfusions of blood or blood products are given to recipients that will  
23 benefit from them. Complications can occur, but can be avoided with careful donor management,  
24 understanding of blood type compatibility, recipient selection and transfusion monitoring.

25 **Clinical challenges:** Feline blood transfusion can be a lifesaving procedure but also detrimental to  
26 donor and recipient without precautions. Cats have naturally occurring alloantibodies to red cell  
27 antigens and severe transfusion reactions can occur with type-mismatched transfusions. Blood  
28 transfusions can also transmit infectious agents to the recipient, so donor testing is essential. Finally,  
29 donors must be in good health, sedated as appropriate and blood collected in a safe and sterile  
30 fashion to optimize the benefit to recipients. Transfusion reactions are possible and can be mild to  
31 severe in nature. Autologous and xenotransfusions may be considered in certain situations.

32 **Evidence base:** These Guidelines have been created by the authors and The International Society of  
33 Feline Medicine (ISFM) based on available literature. They are aimed at general practitioners to  
34 provide a practical guide to blood typing, cross-matching, blood collection and administration.

## 35 **Introduction**

36 Although feline blood transfusions are infrequently performed in primary care veterinary practice,  
37 they can be lifesaving<sup>1,2</sup>. Availability of donors has limited the utility of this technique, but with  
38 growth of blood banks providing access to feline blood, the procedure may become more routine. It  
39 is important that veterinary practitioners select appropriate recipients and donors (in-clinic or stored  
40 blood) and administer blood correctly and with monitoring to mitigate the risks. These guidelines are  
41 written to provide practical information for practitioners on blood types and cross-matching,  
42 indications for transfusion, donor management, recipient preparation and monitoring and potential  
43 complications.

44

## 45 **Feline blood types**

### 46 **Alloantigens**

47 Blood types arise due to the presence of genetically determined antigenic markers on the surface of  
48 red blood cells (RBCs). Blood type antigens are alloantigens as they exist in alternative (allelic) forms  
49 in different cats and can induce an immune response when one blood type is transferred to a cat that  
50 lacks it. One blood group system, the AB system, has been extensively defined in cats. Within the AB  
51 blood group system there are three blood type phenotypes, namely type A, type B and type AB:

- 52 • Blood type A is common – N-glycolylneuraminic acid is the alloantigen on the RBC surface
- 53 • Blood type B is less common, but common in some pedigree breeds e.g. British Shorthair, Birman,  
54 Devon Rex – N-acetylneuraminic acid is the alloantigen on the RBC surface
- 55 • Blood type AB is rare – N-glycolylneuraminic acid and N-acetylneuraminic acid are the alloantigens  
56 on the RBC surface.

57

58 Blood type prevalence varies geographically (see Table 1). Type A is the most common  
59 worldwide and in some breeds 100% of cats are believed to be type A (e.g. Siamese<sup>3</sup>). The

60 prevalence of type B is much lower than type A but it has been reported to be as high as 36%  
 61 in non-pedigrees in Australia <sup>4</sup> and some breeds can contain high numbers of type B cats  
 62 (especially the British Shorthair). Type AB is less common. Blood typing is essential to avoid  
 63 what can be fatal transfusion reactions.

64

65 Table 1: Blood types reported in different geographic locations in different breeds of cat in published  
 66 studies.

Country source of data (reference)	Breed	No. of cats	Type A %	Type B %	Type AB %
UK <sup>5</sup>	Non-pedigree	139	87.1	7.9	5.0
	British shorthair	121	39.7	58.7	1.6
	Birman	24	62.5	29.2	8.3
	Persian	17	88.2	11.8	0
	Other pedigrees	45	77.8	6.7	15.5
UK <sup>3</sup>	Non-pedigree	105	67.6	30.5	1.9
	Siamese	13	100.0	0	0
	Other pedigrees	38	76.3	21.1	2.6
UK <sup>6</sup>	Bengal	100	100.0	0	0
Denmark <sup>7</sup>	Non-pedigree	105	98.1	1.9	0
	Persian	56	96.4	3.6	0
	British shorthair	30	66.7	33.3	0
	Abyssinian	20	100	0	0
	Other pedigrees	33	90.9	9.1	0
Australia <sup>4</sup>	Non-pedigree	355	62	36	1.6
	Siamese	12	100	0	0

Country source of data (reference)	Breed	No. of cats	Type A %	Type B %	Type AB %
	Devon Rex	70	45	54	1.4
	British shorthair	8	38	62	0
New Zealand <sup>8</sup>	Non-pedigree	245	70.6	13.9	0.8
France <sup>9</sup>	Non-pedigree	320	83.8	14.4	1.9
	Pedigree	37	89.2	10.8	0
Central Italy <sup>10</sup>	Non-pedigree	483	89.8	7	3.1
North Italy <sup>11</sup>	Non-pedigree	233	91.0	5.2	3.8 ±
South Italy <sup>11</sup>	Non-pedigree	215	77.2	12.1	10.7
Italy <sup>12</sup>	Ragdoll	61	77.1	4.9	18.0

67

68

## 69 **Alloantibodies**

70 In contrast to dogs, cats can possess naturally occurring alloantibodies against the 'foreign' (non-self)  
71 alloantigen that they are lacking. These alloantibodies will recognise the alloantigens of another cat.  
72 Kittens develop these antibodies at 6-8 weeks of age. In the UK, for example, over 70% of type A cats  
73 have anti-B alloantibodies <sup>13</sup>, which are mostly present at low concentrations, whilst all type B cats  
74 have anti-A alloantibodies, often present in high concentrations. In a report from the USA all type A  
75 cats had anti-B alloantibodies <sup>14</sup>. Type AB cats never have alloantibodies to either type A or type B  
76 antigens. The reaction between the blood type alloantigens and any existing alloantibodies is  
77 observed during cross-matching donor and recipient blood.

78

79 Alloantibodies are responsible for potentially fatal feline blood transfusion reactions that can arise  
80 when cats undergo their first blood transfusion, as they are already present in the cat's circulation,  
81 ready to destroy RBCs of a different blood type phenotype. These alloantibodies are also responsible

82 for neonatal isoerythrolysis <sup>15, 16</sup>, a cause of neonatal death. The severity of a blood transfusion  
83 reaction also depends on the quantity (i.e. higher titres or concentrations worse) and nature (e.g.  
84 strongly agglutinating) of any alloantibodies present in the recipient (or donor).

85

86 **Donor and recipient cats must always be blood typed before transfusions. Type-compatible blood**  
87 **should be administered, i.e type A blood is given to type A cats, type B blood to type B cats, and**  
88 **type AB blood to type AB cats if possible. For type AB cats, if type AB blood is not available, type A**  
89 **blood (or ideally just the type A RBCs following separation) may be given**

90

91 BOX OUT START

## 92 **Blood Typing (Phenotyping)**

- 93 • Blood typing can be performed by submitting anticoagulated blood to a commercial laboratory or  
94 by using an in-clinic test kit.
- 95 • Different kits are available for in-clinic feline blood typing; examples useful for general  
96 practitioners include RapidVet-H cards (DMS Laboratories Inc, Flemington, NJ, USA) based on  
97 agglutination (Figure 1a and Figure 1b) <sup>17</sup>, RapidVet-H immunochromatographic (IC) tests (DMS  
98 Laboratories) (Figure 1c) and the QuickTest A+B (Alvedia, Limonest, France) (Figure 1d to Figure  
99 1h) <sup>17</sup>, also based on IC methodology. The Lab.Test A+B (Alvedia) is similar to the QuickTest A+B  
100 but can be run on multiple (up to 20) samples and requires a microplate, pipette and test tube to  
101 be provided by the user. A gel tube in-clinic blood typing kit is also available (Rapid Vet-H Gel, DMS  
102 Laboratories Inc.) that relies on agglutination; this method includes a step that requires use of a  
103 centrifuge.
- 104 • One study <sup>18</sup> found that the in-clinic QuickTest A+B performed slightly better than the RapidVet-H  
105 card test, and may be more reliable in cats with autoagglutination, but the new RapidVet-H IC test  
106 also appears to be reliable <sup>19</sup>. A more recent publication, focusing on the Lab.Test A+B found it to  
107 outperform the RapidVet-H cards <sup>20</sup>. The study also confirmed that the QuickTest A+B performed

108 well on blood that had been stored in the fridge and at room temperature. A recent study <sup>21</sup>  
109 confirmed that the Lab.Test A+B was very reliable, performing as well as flow cytometry in the  
110 blood type phenotyping of a sample of 49 cats (34 A, 13 B and two AB).

111 • The QuickTest A+B is a migration IC methodology test strip cartridge (Figure 1d to Figure 1h) that  
112 uses monoclonal antibodies (further details not given) to differentiate the blood antigens,  
113 whereas the RapidVet-H cards use a murine monoclonal antibody as the anti-A reagent and a  
114 lectin from *Triticum vulgare* as the anti-B reagent. These different reagents may explain why the  
115 RapidVet-H cards wrongly describe some blood types, as one study <sup>20</sup> showed that the cards were  
116 found to sometimes mistype blood type AB cats as type B and occasionally blood type A cats as  
117 type AB.

118 • An automated method for blood typing is available (QuickVet<sup>®</sup> Feline Blood Typing Test<sup>™</sup>), for use  
119 with the QuickVet<sup>®</sup> Analyzer (Zoetic ApS, Denmark). The QuickVet<sup>®</sup> Diagnostic System consists of  
120 an analyzer and single use disposable test cartridges based on capillary driven microfluidic  
121 technology.

122 • If a sample to be blood typed is from a cat with severe anaemia (packed cell volume [PCV] <14%),  
123 the RBCs can be concentrated by centrifugation of the blood (2-3 mins, remove some of the  
124 plasma supernatant and resuspend the remaining RBCs in the remaining plasma supernatant) to  
125 get a higher concentration of RBCs, and repeat the test; this can be useful if insufficient RBCs reach  
126 the top of the test strip due to the low number present in a very anaemic sample. In a similar way,  
127 if agglutination of the sample precludes movement of the RBCs along the strip, the RBCs can be  
128 washed in phosphate buffered saline and the test repeated.

129 • One study <sup>18</sup> found that some feline leukaemia virus (FeLV) infected anaemic cats were mistyped  
130 using multiple blood typing methods.

131 • Cats with less common blood types (type AB and type B) may be mistyped by commercially  
132 available blood typing in-clinic methods and results should ideally be confirmed at an external  
133 laboratory by a method that uses antibody testing or genetic screening. However, a 'back typing'



134 technique for antibody screening can be used in-clinic where type B is suspected: EDTA blood from  
135 the suspected type B cat is centrifuged at 1000 *g* for two minutes; 30  $\mu$ l plasma is removed and  
136 mixed with 15  $\mu$ l EDTA blood collected from a known type A cat on a glass microscope slide and  
137 observed for agglutination; if positive this confirms the B blood type, as the plasma of the type B  
138 cat contains alloantibodies that agglutinate the type A RBCs.

139 **BOX OUT END**

140

#### 141 **Non-AB feline blood groups**

142 Evidence published in 2007 suggested that other, non-AB, blood group systems existed in cats because  
143 blood transfusion reactions have occurred in cats given AB-matched blood transfusions. A study from  
144 the USA <sup>22</sup> reported the absence of a novel feline RBC antigen named Mik in three of 65 type A cats  
145 tested, in association with the presence of naturally occurring anti-Mik alloantibodies, which mediated  
146 a clinically significant transfusion reaction despite the blood donor and recipient cat being AB-  
147 matched. However, one study in UK cats <sup>23</sup>, and another in German cats <sup>24</sup>, found no evidence of anti-  
148 Mik alloantibodies in the cats sampled in those studies, as no positive cross-matches between AB-  
149 matched blood samples were found in transfusion naïve cats. Other studies <sup>21, 25, 26</sup> have, however,  
150 documented the presence of positive cross-matches between AB-matched blood samples, suggesting  
151 the presence of non-AB blood group systems, although the clinical significance of these is not always  
152 clear and tests for the Mik and other RBC antigens are not available commercially. In the most recent  
153 study <sup>27</sup>, type A cats were evaluated for naturally occurring non-AB alloantibodies by cross-matching  
154 and at least 7% of the type A cats had incompatible cross-matching, documenting the presence of  
155 naturally occurring alloantibodies. Five distinct RBC antigens were hypothesized to be present outside  
156 of the AB blood group system and one of these was thought to correspond to the previously described  
157 Mik antigen.

158

#### 159 **Cross-matching**

160 Cross-matching can be performed in-clinic or at an external laboratory; the latter is ideal as the test  
161 is complex and takes time but obviously this results in a delay in obtaining results. In-clinic cross-  
162 matching kits are available. Based on all existing studies, the clinical effectiveness and need of cross-  
163 matching before a first transfusion remains controversial, however, given that transfusion-naive cats  
164 may have incompatible major cross-matches, cross-matching, as well as blood typing, is  
165 recommended by some before each transfusion where possible in cats<sup>27-29</sup>, although others have  
166 acknowledged that the strength of evidence for this is weak<sup>30</sup>. A recent Australian study<sup>31</sup>,  
167 questioning primarily general practitioner vets, reported that compatibility testing, including cross-  
168 matching, before feline blood transfusions was commonly performed; cross-matching alone in 26%,  
169 blood typing alone in 27.6% and both in 34.1% of respondents.

170

171 In emergency situations cross-matching may not be possible. However, it is strongly recommended  
172 that cross-matching is performed before a transfusion when the recipient has an unknown  
173 transfusion history or has had a previous transfusion reaction or has received a transfusion two or  
174 more days previously. The two day timeline stipulated is because incompatibilities have been  
175 identified by major cross-match testing as early as two days after a first whole blood cross-match  
176 compatible transfusion<sup>24</sup>.

177

## 178 **BOX OUT START**

### 179 **How to perform in-clinic cross-matching**

#### 180 ***Cross-match methodology***

- 181 • 1 ml EDTA blood tube and a 1 ml serum (plain) tube obtained from each of the donor & recipient.  
182 Label tubes.
- 183 • Centrifuge (3,000 rpm for 5 minutes) & separate plasma & serum from RBCs in both tubes. Discard  
184 the plasma if not required for other diagnostic investigations. Store serum in a separate tube &  
185 label.

186 • Wash EDTA RBCs - add 2-3 mls of normal saline solution to the RBCs, mix gently & centrifuge  
187 (3,400 rpm for 1 minute) & remove the supernatant saline. Repeat twice.

188 • After the 3<sup>rd</sup> wash, decant the supernatant & resuspend the RBCs with saline to give a 4% RBC  
189 suspension (0.2 mls RBCs with 4.8 mls saline).

190 • Label four tubes & place the following into each:-

191 Major cross-match 1 drop recipient serum & one drop donor RBC suspension

192 Minor cross-match 1 drop donor serum & one drop recipient RBC suspension

193 Recipient control 1 drop recipient serum & one drop recipient RBC suspension

194 Donor control (optional) 1 drop donor serum & one drop donor RBC suspension

195 • Incubate the tubes for 15 minutes at 37°C

196 • Centrifuge the tubes for 15 seconds (3,400 rpm)

197 • Read the tubes macroscopically and microscopically:

#### 198 ***Macroscopic cross-match reading***

199 In a compatible reaction there should be no clumping nor haemolysis nor agglutination present; when  
200 the tubes are gently rolled and rotated, RBCs should be able to float off freely from the centrifuged  
201 “pellet” of RBCs. The supernatant should be free of haemolysis (Figure 2).

#### 202 ***Microscopic cross-match reading***

203 A drop of the RBC/serum mixture from the tubes is placed on a microscope slide, cover slipped &  
204 viewed microscopically (within 60s of placing the blood on a microscope slide). The RBCs should be  
205 visible as individual cells & not in clumps. Rouleaux formation, where RBCs stick together as stacks of  
206 coins, can look macroscopically like agglutination but rouleaux formation (Figure 3a) can be  
207 differentiated from agglutination (Figure 3b) on microscopic examination. Rouleaux formation is not  
208 a clinical concern but agglutination indicates an incompatible cross-match reaction.

209

210 NB. Others have modified the above protocol to use plasma, rather than serum (as both can be used  
211 for cross-matching<sup>32</sup>), along with a 3-5% suspension of RBCs in phosphate buffered saline (rather than

212 saline), and to not perform the donor control but just the recipient control test<sup>24</sup>. The study describing  
213 this modified method also reported that cross-matching could be done with as little as 250 µl (0.25  
214 mls) of blood, which is encouraging as minimising the amount of blood taken from anaemic cats is  
215 important.

216

#### 217 **How to perform routine in-clinic cross-matching using kits**

218 In-clinic cross-match kits are available such as the RapidVet-H Major and Minor Cross-match kits (DMS  
219 Laboratories), which use serum, and the QuickTest XM EmMatest test or Lab.Test XM (both Alvedia),  
220 which use plasma. All kits can be used to perform both the major and minor cross-matches. A feline  
221 Gel.Test (Alvedia), which uses plasma, is also available for cross-matching, but this requires the  
222 mandatory use of a specific centrifuge. With all such kits, instructions should be carefully followed,  
223 but studies have yielded variable results with different methods and it is difficult to compare results  
224<sup>27</sup>.

#### 225 **BOX OUT END**

226

#### 227 **BOX OUT START**

#### 228 **How to perform emergency cross-matching**

229 If cross-matching is required in an emergency, the following method can be used which omits the  
230 washing of RBCs described above:

- 231 • EDTA is collected from donor and recipient then centrifuged to separate plasma and RBCs
- 232 • Major cross-match: 2 drops of recipient plasma and 1 drop of donor RBCs (so ~ major cross-  
233 match) are then placed on a glass microscope slide and the slide examined microscopically for  
234 agglutination between 1 and 5 minutes, as described above. Agglutination must be differentiated  
235 from rouleaux formation microscopically as described above for routine cross-matching
- 236 • Controls should also be performed using recipient plasma and RBCs and, if possible, donor plasma  
237 and RBCs, and examined microscopically

- 238 • Note that drying out of blood on the slide can result in rouleaux formation but this takes > 5  
239 minutes to occur

240 **BOX OUT END**

241  
242 **Selecting a donor**

243 ***Infectious disease screening***

244 Risks from transfusion include the transmission of infectious agents from donor to recipient, which  
245 can be avoided largely through donor selection and screening. Such a process must vary between  
246 countries/regions and practices and will depend on locally endemic diseases, the practicalities in  
247 selecting donors that do not carry them and the cost/availability of screening compared to the risk of  
248 not having any available blood.

249

250 In addition to the considerations above, individual donor factors such as indoor/outdoor status,  
251 ectoparasite control and time of last testing will influence the likelihood of infectious agent presence.  
252 These will in turn determine which agents should be screened for, the most appropriate methodology  
253 and also the required frequency, which may be deemed to be annually, or at the time of every blood  
254 donation if there is a high risk of novel exposure or intermittent circulation of a pathogen <sup>33,34</sup>.

255

256 ***Core infectious agents to test blood donors for***

257 ***Haemotropic Mycoplasmas***

258 The pathogenic *Mycoplasma haemofelis* can be transmitted by blood products, although it appears to  
259 be inactivated during storage of whole blood for one week <sup>35</sup>. Blood smear evaluation is insensitive  
260 for diagnosis and also lacks specificity and thus the diagnostic test of choice for screening blood donors  
261 is PCR. PCR testing for '*Candidatus Mycoplasma haemominutum*' (which may survive for a week in  
262 stored blood <sup>35</sup>) and '*Candidatus Mycoplasma turicensis*' can also be considered, but as these agents

263 are of lower pathogenicity<sup>36</sup>, donors may not be excluded if positive for these organisms if the donor  
264 pool is very limited. Ideally, however, cats should be negative for these agents too.

265

266 *Bartonella* spp.

267 Numerous *Bartonella* species can be present in the blood of cats and have been associated with  
268 several clinical conditions<sup>37</sup>. *Bartonella henselae* has been shown to survive in stored blood<sup>38</sup>. Donors  
269 should ideally be serology and PCR negative for *Bartonella* spp. but seropositivity may be common in  
270 endemic areas and sensitive testing methods are not always readily available. Seropositive cats may  
271 have intermittent bacteraemia<sup>39</sup> but can be considered for donation if PCR negative.

272

273 *Feline leukaemia virus/feline immunodeficiency virus (FIV)*

274 Both FeLV and FIV can be transmitted by blood transfusion and thus donor cats need to be negative  
275 for both of these agents<sup>40</sup>. Antigen tests for FeLV are commonly available, such as ELISA or IC in-clinic  
276 tests, but proviral DNA testing (by PCR) should be performed, if at all possible, as transmission of FeLV  
277 infection via blood transfusion has been documented by FeLV provirus positive, antigen negative  
278 blood (e.g. PCR positive, ELISA negative)<sup>41</sup>. Antibody tests for FIV are commonly available as ELISA or  
279 IC in-clinic tests too and cats should be negative for FIV antibody before being used as donors.  
280 Although certain FIV antibody tests may be able to differentiate true FIV infected cats from those cats  
281 that have been vaccinated for FIV (in those countries where FIV vaccination is, or has been, available  
282 for use in cats), it is recommended that only FIV antibody negative cats are used as blood donors due  
283 to the potential for confusion in interpretation of test results<sup>42</sup>.

284

285 ***Additional agents to consider testing blood donor cats for***

286 *Anaplasma* spp.

287 *Anaplasma phagocytophilum* can cause illness in cats, can be transmitted by blood inoculation, and  
288 exist as a persistent infection<sup>43,44</sup>. Donor cats with potential tick exposure (particularly *Ixodes ricinus*)

289 from endemic areas should ideally be screened by serology and PCR, if available. Seropositive, PCR-  
290 negative cats may be used in endemic regions if no other suitable donor can be identified. Infection  
291 with *Anaplasma platys* has been documented in cats<sup>43</sup> and so cats living in areas endemic to  
292 *Rhipicephalus* spp. ticks should be screened for this agent by PCR.

293

294 *Cytauxzoon felis*, *Babesia felis*, *Ehrlichia canis*, *Leishmania infantum* and *Neorickettsia risticii*

295 These are all vector-borne agents<sup>43-49</sup>, which may be transmittable by blood products. Although pre-  
296 donation physical examination and blood smear examination should minimize transmission risk, the  
297 optimal standard would be to have cats negative by PCR, if available, for these agents in blood donor  
298 cats living in endemic areas.

299

### 300 **Other infectious agents**

301 Screening for coronavirus, *Rickettsia felis* and *Toxoplasma gondii* is not recommended for donor cats.  
302 Transmission of these agents by blood products has not been documented.

303

### 304 **Donor characteristics**

305 Donors should be healthy, between one and eight years old and with a lean body weight above  
306 4.5kg. They should be of calm temperament and easy to handle to reduce sedation requirements.

307 They should be current with all applicable vaccinations and parasite control and ideally live indoors  
308 without recent introduction of other cats to the household, to reduce their exposure to infections.

309 No other recent medications should have been given and they should never have received a  
310 transfusion nor be currently pregnant. Cats that have previously had a litter may still be donors.

311 Annual health screening of potential blood donors, including haematology and serum biochemistry  
312 profiles, is recommended. In addition, a complete history and physical examination, as well as

313 determination of PCV or haemoglobin concentration, should be completed before each blood  
314 collection.

315

316 Occult cardiomyopathy is excluded with echocardiography by some clinicians prior to allowing cats  
317 to join a donor program, given that up to 30% of cats with cardiac disease will not have a murmur <sup>50</sup>.  
318 However, others would omit echocardiography and exclude cats with murmurs, gallops or  
319 arrhythmias from donation, or perform quantitative NT-proBNP serum testing, which has been shown  
320 to reliably discriminate normal cats from those with occult cardiomyopathy <sup>51</sup>.

321

## 322 **BOX OUT START**

### 323 **Donor selection criteria**

- 324 • Between one and eight years of age
- 325 • Lean body weight above 4.5kg
- 326 • Calm temperament
- 327 • Up to date with relevant vaccination, worming and ectoparasite treatments
- 328 • No current medications
- 329 • Ideally living indoors
- 330 • No history of having received a transfusion
- 331 • Annual haematology and serum biochemistry screening within reference intervals
- 332 • FeLV antigen and FIV antibody testing negative (can be done in-clinic) and FeLV provirus PCR  
333 negative
- 334 • Haemotropic mycoplasma & *Bartonella* spp. PCR testing negative
- 335 • Negative for vector borne pathogens in endemic areas

## 336 **BOX OUT END**

337

### 338 **Indications for blood transfusion**



339 Due to restrictions on storage of animal blood, most cats in the UK and in Europe in need of a blood  
340 transfusion will receive fresh whole blood (FWB), which contains all of the blood components: RBCs,  
341 platelets, coagulation factors, and plasma proteins. However, in countries where blood storage is  
342 available, feline FWB donations are processed into packed red blood cells (pRBCs) and fresh-frozen  
343 plasma (FFP) components. The use of these blood components has many advantages including  
344 extending resources, allowing specific replacement therapy, and potentially reducing the number of  
345 transfusion reactions.

346

### 347 **RBC products**

348 Red blood cell products, namely FWB and pRBCs, increase the oxygen-carrying capacity of the blood  
349 and thereby improve oxygen delivery to tissues. While FWB and pRBC transfusions can be used  
350 interchangeably in most anaemic cats, administration of pRBCs would be preferable to FWB to  
351 those, for example, with underlying cardiac disease to help avoid circulatory overload, and  
352 depending on the cause of the anaemia (e.g. if due to haemolysis rather than blood loss). The  
353 decision to administer a RBC product transfusion is frequently based on measurement of the cat's  
354 PCV, haematocrit, or haemoglobin concentration. However, a "transfusion trigger" or threshold PCV  
355 below which a RBC transfusion is administered has not been clearly defined in human or veterinary  
356 medicine, and accompanying clinical signs are very important to consider in deciding if a transfusion  
357 should be considered. In two recent studies involving RBC transfusions in more than 265 cats, the  
358 pre-transfusion PCV was 15% (median value <sup>25</sup>) and 17% (mean value <sup>26</sup>), with a range of 5-40%. In  
359 some cats with peracute blood loss and hypovolaemia, RBC transfusions may be indicated even  
360 though their PCV is normal. These patients will predictably develop a low PCV following fluid  
361 resuscitation with asanguineous fluids.

362

### 363 **BOX OUT START**

364 The decision to transfuse RBC products is based on several factors in addition to PCV, including the  
365 onset of anaemia (if acute in nature, there may be more of a need compared to chronic onset  
366 anaemia), presence of ongoing RBC losses and, most importantly, the clinical signs of the patient.  
367 Tachycardia, bradycardia, bounding peripheral pulses, collapse, lethargy, and weakness are all signs  
368 that should prompt consideration of RBC transfusion.

#### 369 **BOX OUT END**

370

371 In approximately 5-25% of cats, ineffective erythropoiesis and blood loss are the most common  
372 general causes of anaemia reported in cats receiving RBC transfusions, with haemolysis noted less  
373 frequently<sup>25, 26, 29</sup>. Underlying conditions frequently associated with development of non-  
374 regenerative anaemia in cats, and the potential need for a RBC transfusion, include chronic kidney  
375 disease, lymphoma, systemic inflammatory disease, infectious diseases, and bone marrow disorders  
376<sup>52</sup> and chronic unspecified diseases<sup>29</sup>. An often-overlooked factor contributing to development of  
377 anaemia in hospitalized critically ill cats is repeated phlebotomy for blood sampling, with 74% of  
378 non-anaemic cats developing anaemia during an ICU stay in one study<sup>53</sup>. In this study cats that  
379 required a pRBC transfusion had significantly more daily blood samples taken (median 3, range 1–6)  
380 than cats that did not require a transfusion (median 2, range 1–4).

381

#### 382 **Plasma products**

383 Plasma separated from RBCs within eight hours of blood collection is referred to as *fresh plasma*, but  
384 in countries where stored veterinary blood products are available, fresh plasma is more often frozen  
385 after preparation and stored (-20 to -30°C) for up to one year; this type of plasma is referred to as  
386 *fresh-frozen plasma* (FFP). Fresh plasma and FFP contain haemostatic proteins (coagulation factors,  
387 von Willebrand factor, anticoagulant proteins, and fibrinolysins), albumin and immunoglobulins. The  
388 main indication for use of fresh plasma or FFP is bleeding due to inherited or acquired  
389 coagulopathies, but its use has also been reported in cats with hypotension, liver disease, neoplasia

390 and sepsis<sup>54</sup>. Although the benefit of prophylactic administration of plasma to cats with a  
391 coagulopathy (but not showing clinical signs of bleeding) undergoing an invasive procedure is  
392 unclear, it was reported to be the main reason for FFP transfusions in cats in another study<sup>55</sup>.  
393 Anticoagulant rodenticide toxicity is uncommon in cats compared to dogs, but may occur after  
394 consumption of poisoned prey, and FFP as well as FWB may be included in the treatment protocol<sup>55-</sup>  
395 <sup>57</sup>.

396 Hereditary haemostatic disorders are diagnosed infrequently in cats. There are two case reports of  
397 type 3 von Willebrand disease (VWD)<sup>58,59</sup> and sporadic reports of haemophilia A and B (<sup>55, 60, 61</sup>)  
398 causing bleeding in cats. Plasma would be appropriate to provide replacement of von Willebrand  
399 factor in cats with VWD or factor VIII or IX in cats with haemophilia A or B, respectively, experiencing  
400 bleeding, though FWB would be an alternative if fresh plasma or FFP was not available or the cat  
401 was also anaemic.

402

403 The effect of plasma on colloid osmotic pressure is less than that of synthetic colloids, and the use of  
404 plasma for volume expansion is not recommended<sup>62</sup>.

405

#### 406 **Platelet products**

407 Due to technical challenges associated with preparing platelet-rich plasma from a small volume  
408 feline FWB unit, cats in need of a platelet transfusion generally are administered FWB, although this  
409 will not provide adequate platelets to correct thrombocytopenia. There are few indications for  
410 platelet transfusions in cats, but include uncontrolled or life-threatening haemorrhage (e.g.  
411 pulmonary haemorrhage) with thrombocytopenia or thrombopathia, and possibly massive  
412 transfusion (rare but is when a high number of pRBCs have been given, which can cause by a  
413 dilutional effect on the recipient's clotting factors and platelets). While platelet disorders are  
414 uncommon in cats, primary immune-mediated thrombocytopenia can lead to severe blood loss  
415 anaemia, which can be managed with FWB transfusions<sup>63</sup>. Cats with bleeding secondary to a

416 thrombopathia typically require administration of functional platelets (for practical reasons in the  
417 form of FWB) to control bleeding <sup>64</sup>.

418

### 419 **Xenotransfusion**

420 Xenotransfusion is defined as the transfer of blood from one species to another. Successful  
421 administration of whole blood or pRBCs from dogs to cats has been documented and can be  
422 performed if absolutely necessary and only as a single, one-off transfusion <sup>65, 66</sup>. In some  
423 circumstances, dog blood may be more readily available than cat blood, and available in larger  
424 volumes, leading to its occasional use <sup>31</sup>. Potential indications for xenotransfusion include previous  
425 transfusion reaction to feline blood products, insufficient time to blood type the recipient, non-  
426 availability of suitable feline blood products in sufficient quantities or financial constraints.

427 Xenotransfusion is mainly used for short-term stabilisation of an anaemic cat, allowing time for  
428 investigations or to obtain compatible feline blood or time for endogenous erythropoiesis to correct  
429 the anaemia <sup>65-68</sup> with or without appropriate treatment. Typically, 30-50 mls of canine blood is  
430 administered using the same administration rates (see later) as feline blood.

431

432 Antibodies to donor canine RBCs are detected 4-7 days following transfusion of canine blood into cats  
433 <sup>67</sup>, resulting in destruction of donor RBCs and a late haemolytic reaction and hence a shorter life span  
434 of the donor canine RBCs compared to the life span of appropriately typed feline RBCs (30 days <sup>69</sup>).

435 Subsequent repeat transfusion of canine blood to the cat will result in a severe transfusion reaction,  
436 anaphylaxis and likely death <sup>65</sup>. Reported short-term complications following xenotransfusion are

437 similar to cat to cat transfusions (allotransfusions), with minor febrile non-haemolytic transfusion  
438 reactions seen in 12% of cases <sup>68</sup>. A severe acute anaphylactic transfusion reaction immediately upon

439 administration of canine whole blood to a transfusion naïve cat has been reported (Korman, personal  
440 communication). Delayed haemolysis, often manifesting as icterus, occurs in 64% of cats at a median

441 of 2 days (range of 1 to 6 days) after transfusion <sup>68</sup>, meaning the benefits of xenotransfusion are short

442 lived compared to allotransfusion. Pre-xenotransfusion cross-matching results do not appear to  
443 predict the development of transfusion reactions<sup>67,68</sup>. In one study<sup>68</sup> the long-term outcome of cats  
444 given xenotransfusions appeared to be associated with their primary disease and those that recovered  
445 appeared to have no notable adverse effects that could be directly attributed to xenotransfusion.

446

#### 447 **Chemical restraint of the donor for blood transfusion**

448 It is possible to perform blood collection in conscious cats with a skilled veterinary care team;  
449 however, these patients must be cooperative and blood donation may be a negative experience for  
450 donors. Movement during donation and signs of anxiety have been reported in conscious cats much  
451 more often than in sedated cats<sup>70</sup>. Additionally, stress produced by handling may affect the cellular  
452 and chemical composition of the blood (e.g. hyperglycaemia)<sup>71</sup>. Therefore, chemical restraint or  
453 general anaesthesia is now commonly used for both in-clinic and client-owned feline donors. The  
454 choice of a short-term (30 minutes) protocol for chemical restraint will avoid an uncomfortable  
455 experience for the cat and failed, repeated interventions that could produce injuries to the  
456 veterinary care team. It will also influence owner satisfaction with the donor experience<sup>72</sup>.  
457 Chemical restraint for feline blood donors is no different to any other anaesthetic procedure in the  
458 sense that preoperative examination and appropriate fasting (6 hours) are mandatory. An  
459 anaesthetic plan, including monitoring and careful choice of dosage regimens, is required. The use of  
460 local anaesthetic creams (see Figure 4) and pheromones may be part of the overall management of  
461 the patient to help reduce stress.

462

463 The intravenous route of administration is often preferred due to the rapid onset of action and the  
464 use of lower doses of anaesthetic agents when compared with the intramuscular and subcutaneous  
465 routes. Several studies have reported the feasibility, and effects, of different drug combinations on  
466 major blood analytes in cat donors (see Table 2). Overall, each protocol has its unique advantages  
467 and disadvantages. Ideally, the drug combination should have a short onset with adequate depth

468 and duration of action and include a smooth and rapid anaesthetic recovery with minimal  
 469 cardiorespiratory depression on the donor. The choice will be also dependent on drug availability  
 470 and the familiarity of the veterinary care team with the protocol. Eye lubricant should be applied to  
 471 all cats regularly (every 10-15 minutes) to avoid eye ulcers and lesions. Ideally, the cat should return  
 472 to its normal behaviour, and eat and drink, shortly after the end of anaesthesia.

473

474  $\alpha$ 2-adrenergic receptors agonists (xylazine, medetomidine and dexmedetomidine) are to be avoided  
 475 for several reasons (see Table 2). Propofol produces significant cardiorespiratory depression and  
 476 may lead to the formation of Heinz bodies, so is also best avoided. Ketamine is often used as part of  
 477 drug protocols; however, it should not be administered alone since muscle jerks, hallucinogenic  
 478 behaviour, hyperaesthesia and emergency delirium (growling, biting, scratching, lunging at the cage)  
 479 have been observed. Sevoflurane has been used for feline blood donation since induction of, and  
 480 recovery from, anaesthesia is rapid and predictable (Table 2).

481

482 Table 2: Summary of different drug combinations that can be used in blood donors and their effect  
 483 on major blood analytes. RBC: red blood cell; HCT: haematocrit; Hb: haemoglobin; WBC: white blood  
 484 cells; PCV: packed cell volume, IV intravenous, IM intramuscular.

Drugs	Dose or dosage or inhalant concentration commonly reported	Comments	Changes in blood analytes reported in studies	References
Ketamine and diazepam	10 mg ketamine + 0.5 mg diazepam, both IV	Protocol for short-term venipuncture (5 minutes). Short onset and duration of action with excellent chemical restraint but may not be enough to complete phlebotomy. Note: diazepam should not be administered IM	Minimal decreases in plasma triglycerides and albumin, and minimal increases in activated partial thromboplastin and prothrombin times, likely without clinical relevance	<sup>73</sup>
Ketamine and midazolam	4-6 mg/kg ketamine + 0.4 mg/kg midazolam, both IM	Mixed in the same syringe for IM injection. Prolonged anaesthetic effects, with ataxia and recumbency for up to 4-6 hours after phlebotomy. Alternative protocols include the addition	Decreases around 24-25% in RBC count, Hb concentrations and PCV after higher doses of ketamine (10 mg/kg) and midazolam (0.5 mg/kg) IV. Based on	<sup>74-76</sup>

Drugs	Dose or dosage or inhalant concentration commonly reported	Comments	Changes in blood analytes reported in studies	References
		of butorphanol (0.3 mg/kg) or buprenorphine (0.01 mg/kg) IM. Hyperthermia may occur with ketamine-based protocols	these PCV changes, some donors may be falsely diagnosed with anaemia	
Dexmedetomidine and butorphanol	0.01 mg/kg dexmedetomidine + 0.2 mg/kg butorphanol, both IM	Ease of administration with short onset of action and possibility of dexmedetomidine reversal with atipamezole (0.1 mg/kg IM). Good muscle relaxation. Adverse effects include emesis, bradycardia, increased systemic vascular resistance and decreases in cardiac output. Peripheral vasoconstriction poses an additional challenge to venous catheterization and blood collection; several donations were aborted due to this. Higher doses of dexmedetomidine might be required in some cats	Decreases in RBC count, Hb concentration and HCT values (i.e. sequestration of erythrocytes by the spleen induced by reduced sympathetic activity)	72 74 77
Alfaxalone and butorphanol	2 mg/kg alfaxalone + 0.2-0.4 mg/kg butorphanol, both IM	Minimal cardiorespiratory changes. Large volume of IM injection. Rapid recovery from anaesthesia (just over 30 minutes). Additional sedation or gentle physical restraint might be required in some cats; further administration of alfaxalone (0.1 mg/kg IV) can be used but will prolong duration and recovery of anaesthesia. In the author's experience (PS), twitching can be observed	No changes in complete blood count or serum biochemical values in experimental cats after doses of 5 mg/kg and 15 mg/kg IV	72, 78, 79
Tiletamine and zolazepam	2.5 mg/kg of each of tiletamine and zolazepam, both IM	Short onset of action. Hypothermia can be observed. Increases in heart rate and blood pressure due to hypovolemia and drug-induced sympathetic stimulation.	RBC, HCT, Hb, WBC, platelet, neutrophil and monocyte counts decreased, and lymphocyte, eosinophil and basophil counts increased after blood collection (not statistically significant)	80
Sevoflurane	Mask or "box" induction with sevoflurane (4-5% for induction followed by 2-3% for maintenance using 2 L/min of oxygen)	Potentially stressful to the cat. Anaesthesia is best induced by wrapping the cat in a towel with gentle restraint using a snug-fitting mask to the face. Possibility of	Not reported	75

Drugs	Dose or dosage or inhalant concentration commonly reported	Comments	Changes in blood analytes reported in studies	References
		profound agitation during recovery. Environmental exposure of the veterinary care team to the inhalant anaesthetic. Higher prevalence of hypotension when compared with ketamine combinations. An endotracheal tube should be available if intubation is required		

485

486 Monitoring of mucous membrane colour, temperature, pulse and respiration rate of the donor cat  
487 should be performed throughout the anaesthetic procedure and blood collection. Pulse oximetry  
488 (SpO<sub>2</sub>) can be used as a non-invasive method to determine the percentage of arterial haemoglobin  
489 saturated with oxygen. The device can be placed over the plantar digit of a pelvic limb during  
490 collection. Hypothermia is prevented by positioning the cat over a circulating warm water blanket or  
491 other warming device (with appropriate safety measures). Blood donation implies controlled losses  
492 of up to 20% (40-60 ml) of a cat's blood volume over a short period of time. As hypotension (systolic  
493 < 80–90 mmHg, mean < 60–70 mmHg, and diastolic <40 mmHg) is commonly observed with both  
494 injectable and inhalant anaesthetic protocols<sup>75,81</sup>, blood pressure monitoring is recommended due  
495 to potential hypovolaemia and the effects of anaesthetics. Depending on the donor protocol,  
496 balanced crystalloid solutions may be provided via intravenously or via the subcutaneous route  
497 immediately after donation. Arterial partial pressure of oxygen can decrease during chemical  
498 restraint and oxygenation via a tight facemask is recommended. Desaturation (SpO<sub>2</sub> < 90%) indicates  
499 hypoxaemia and oxygenation must be administered in this case especially with protocols using a  
500 combination of opioid-dexmedetomidine-ketamine or alfaxalone<sup>82</sup>. Other measures may be  
501 required including drug reversal and termination of the procedure.

502

503 **Practical blood collection**



504 The anticoagulant-preservative solutions most often used for collection of blood for transfusion  
505 purposes are ACD-A (anticoagulant citrate-dextrose solution), CPD (citrate-phosphate-dextrose) or  
506 CPDA-1 (citrate-phosphate-dextrose-adenine). The volume of anticoagulant used and the duration  
507 of time for which the blood product can be stored vary depending on the anticoagulant-preservative  
508 solution and the collection method. ACD-A, CPD and CPDA-1 typically are used in a ratio of 1 ml  
509 anticoagulant to 7ml of blood. Sodium citrate (3.2 or 3.8%) alone (without RBC preservatives) may  
510 be used at a ratio of 1 ml anticoagulant to 9 ml of blood if the blood is to be administered within 24  
511 hours of collection. Use of heparin as an anticoagulant for blood collected for transfusion is not  
512 recommended.

513

514 Blood collection systems are described as “open” or “closed”. A closed system is one in which the  
515 only exposure of the collection bag or its contents to air prior to administration is when the needle is  
516 uncapped to perform venipuncture during collection. An open system is one in which there is one or  
517 more additional sites of potential bacterial contamination during blood collection or processing, with  
518 examples being the use of syringes or empty bags with added anticoagulant to collect blood, as  
519 frequently used in cats (Figure 5). Blood products collected in an open system should be ideally  
520 administered within four hours, or if stored in a refrigerator (1-6°C) they should be administered  
521 within 24 hours.

522

523 A commercially available feline closed collection system (Figure 6a and Figure 6b) has been  
524 evaluated for storage of feline blood for 35 days, with one of eight blood units showing bacterial  
525 growth (*Serratia marcescens*) on day 35 but not day zero<sup>83</sup>, highlighting the fact that bacterial  
526 contamination of a blood unit during collection is an issue regardless of whether using an open or  
527 closed collection system. Another closed feline blood collection system was recently evaluated  
528 which permits blood collection by suction using a vacuum chamber, which accelerated the process  
529 without being detrimental to the blood donor, therefore optimizing collection<sup>84</sup>. In addition, this

530 study directly compared this closed system to an open system, for evidence of bacterial  
531 contamination, and did not observe any difference in bacterial contamination of the units between  
532 the two collection systems<sup>84</sup>. Also, blood units and blood products collected using open systems  
533 have previously been stored successfully without microbial growth, although all blood banking was  
534 done by experienced staff and blood was collected with appropriate aseptic collection methods,  
535 processing and careful storage to prevent contamination<sup>85</sup>, which may have contributed to this  
536 result.

537

538 The volume of blood that may be collected safely from feline donors is approximately 20% of their  
539 blood volume (blood volume approximately 50-60 ml/kg) every four weeks; thus a recommended  
540 volume limit is approximately 10-12 ml/kg for cats based on lean body weight<sup>81</sup>. For practical  
541 purposes, a routine feline blood collection is a total volume of approximately 40-60 ml, including  
542 anticoagulant. Most volunteer donor schemes using client-owned pets as donors extend the  
543 donation interval to every 8-12 weeks, and at this frequency supplementation with iron is not  
544 required unless a deficiency is detected.

545

546 The jugular vein is the recommended venipuncture site in cats because of its size and accessibility.  
547 Strict aseptic technique minimizes the possibility of bacterial contamination (see text box for  
548 collection procedure). In a retrospective observational study of 115 feline blood donations (70 non-  
549 sedated and 45 sedated), evidence of cardiovascular or respiratory distress was noted in three non-  
550 sedated cats after donation; panting, tachypnoea, and collapse were each observed in one cat, all of  
551 which were determined to be normotensive within minutes of the untoward event<sup>70</sup> and recovered  
552 fully. Further study is required to assess the complication rate between sedated and non-sedated  
553 donors but, in most cats, sedation is preferred to reduce patient anxiety and potential movement  
554 and trauma to the jugular vein during donation. Assessment of patient demeanour should form part  
555 of the pre-donation assessment and examination.

556

557 After blood collection and during recovery from chemical restraint donors should continue to be  
558 monitored as indicated above (mucous membrane colour, pulse and respiratory rate, and systolic  
559 blood pressure if indicated) and optionally provided subcutaneous or intravenous fluids. The patient  
560 may be discharged once vital parameters are in the normal range, and ideally after food is eaten,  
561 before discharge.

562

563 **BOX OUT START**

564 **Fluid therapy for feline blood donors**

565 Provision of fluid therapy prior, during or after collection of blood from a donor varies between  
566 centres and clinicians. No detrimental effects are reported in large donor programs when crystalloid  
567 fluids are not supplemented (Penn Animal Blood Bank, personal communication) and other authors  
568 provide 90 ml lactated Ringer's solution subcutaneously prior to collection of the donation, and the  
569 same solution is administered intravenously at 10 ml/kg starting halfway through the donation <sup>86</sup>.  
570 Others supplement with a balanced crystalloid solution such as Hartmann's or lactated Ringer's  
571 solution at 2-3 times the volume of blood collected, given immediately intravenously after the  
572 donation is completed <sup>87</sup>.

573 **BOX OUT END**

574

575 **BOX OUT START**

576 **Feline blood collection procedure using open system** (equipment shown in Figure 5)

- 577 1. A pre-donation blood sample can be collected from an intravenous catheter or peripheral  
578 vein for measurement of PCV or haemoglobin via a haemoglobin monitor. Perform the  
579 blood collection only if PCV or haemoglobin is in the reference interval.
- 580 2. Syringes (several 10, 20, or one 60 ml) are pre-filled with an appropriate volume of  
581 anticoagulant (1 ml of ACD-A, CPD or CPDA-1 per 7 ml of blood to be collected).

- 582 3. The donor is restrained in the position preferred by the phlebotomist e.g. a sitting position  
583 with head raised (especially if not sedated); if sedated, the cat can be placed in sternal  
584 recumbency with forelimbs over the edge of a table and the head raised (Figure 6a) or in  
585 lateral (Figure 6b and Figure 6c) or dorsal recumbency with the neck extended (Figure 6d).
- 586 4. The hair over the jugular vein is clipped and the venipuncture site is prepared using an  
587 aseptic technique (Figure 6c).
- 588 5. Pressure is applied at the thoracic inlet to raise the jugular vein, and a butterfly catheter (19  
589 or 21 gauge) is inserted into the jugular vein.
- 590 6. The phlebotomist keeps the butterfly needle within the jugular vein as still as possible,  
591 whilst each syringe is filled in turn and gently rocked to ensure mixing of blood and  
592 anticoagulant during collection by an assistant. Sometimes occlusion of both jugular veins  
593 can accelerate blood collection if syringe filling flow has slowed down.
- 594 7. After collection, the butterfly needle is removed from the jugular vein, and pressure is  
595 applied to the venipuncture site to prevent haematoma formation.

596 If a blood clot is found in one syringe only, that syringe should be discarded if possible.

597 A more detailed step-by-step photo guide of blood collection is available elsewhere <sup>87</sup>

598 BOX OUT END

599

600 BOX OUT START

601 **Feline blood collection procedure using closed system** (equipment shown in Figure 7)

602 A TEC 724 blood collection kit for cats (Futurlab Srl, Limena, Padova, Italy) can be used for closed  
603 blood collection, as previously described <sup>83, 88</sup>. Figure 7a and Figure 7b show the system set up with a  
604 description of its use below.

- 605 1. Close clamp 3, leave clamps 1 and 2 open.
- 606 2. Push the plunger of the 10 ml syringe 'C' up to the first thick black permanent marker line to put  
607 around 3 ml of anticoagulant into the system (on 1<sup>st</sup> occasion before the first withdrawal of blood

608 from the donor make sure the anticoagulant solution reaches the break-valve 'B' to prevent  
609 subsequent coagulation in the collection line. This means around 3 ml of anticoagulant will be in  
610 the closed collection system to go into the blood collection syringe 'D' alongside around 20 ml of  
611 blood aspirated from donor; this maintains the approximate correct 1:7 ratio of anticoagulant to  
612 blood).

613 3. Close clamp 1.

614 4. Remove the cap of the luer lock connection 'A' and connect it to the butterfly needle of the  
615 desired gauge to collect blood from the donor cat.

616 5. Obtain donor jugular vein access with the butterfly needle, ensuring it is correctly inserted and  
617 then held still.

618 6. Break the break-valve 'B' (this valve means that the donor blood is never in contact with the air,  
619 ensuring the system remains closed).

620 7. Draw the 20ml of blood into the 'D' syringe via aspiration – the blood comes into contact with,  
621 and will mix with, the anticoagulant previously placed in the system.

622 8. Once the 'D' syringe has been filled with blood mixed and anticoagulant, open clamp 3 and push  
623 the plunger of syringe 'D' so that the blood goes through the unidirectional valve 'E' into the  
624 primary bag 'F' (see Figure 7b).

625 9. Close clamp 3, open clamp 1 and then repeat steps 2, 7 and 8.

626 10. Repeat step 9 until collection of blood complete; the anticoagulant solution allows collection of  
627 up to 60 ml  $\pm$  10% of blood (primary bag capacity is 80 ml).

628 11. When the blood collection is complete, close clamp 2 and remove the butterfly needle from the  
629 donor, applying pressure to the jugular vein.

630 12. Separate the equipment at the point indicated by the black cross in Figure 6a by means of an  
631 electric or manual sealer (a sealer is a tool used to close off the blood bag by sealing the tube  
632 using heat or metal; used mainly in blood banks, but available for purchase, but metallic clamps  
633 can be used if not available) – this separates the blood-filled primary bag 'F' of blood (and the

634 plasma satellite bag 'I') from the syringes and rest of the kit.

635 13.To infuse the collected blood in 'F', connect the luer lock infusion adapter 'K' (provided with the  
636 kit) to the valve 'G' and remove the butterfly cap from the other end to connect with an infusion  
637 set with spike. If not given to the recipient immediately, the collected blood can be stored at 4-  
638 6°C. It is possible to take samples from the bag by connecting a luer lock syringe to the needle  
639 free valve 'G'.

640 14.Although very unlikely in general practice, as blood bank centrifuges are usually only available in  
641 blood banking organisations, the closed collection kit shown can also be used to divide the FWB  
642 collected into one packed red blood cell (pRBC) unit and one plasma unit. This is done by  
643 centrifugation of the primary and satellite bags in specialized blood bank centrifuges, then  
644 breakage of the break-valve 'H' and transfer of plasma to the bag 'I' which is then sealed at the  
645 position of the blue cross in Figure 7a. Plasma can then be stored frozen at -20°C for up to one  
646 year (as fresh frozen plasma - FFP) or from one to five years (as frozen plasma - FP). Samples from  
647 the plasma bag can be taken by connecting a luer lock syringe to the needle free valve 'J'. The  
648 luer lock infusion adapter 'K' can be attached to the valve 'J' and connected to an infusion set  
649 with spike for administration.

650 BOX OUT END

651

652 While most cats in need of a transfusion in clinical practice receive FWB, the high erythrocyte  
653 sedimentation rate of feline blood allows for the separation of plasma and RBCs by simply placing  
654 blood-filled syringes upright for approximately one hour at room temperature<sup>89</sup> (Figure 8a). Plasma  
655 can then be expressed into a transfer pack and frozen within 8 hours of collection, if not  
656 immediately needed (Figure 8b). Packed RBCs can then be administered directly from the syringe or  
657 expressed into a transfer pack containing 10 ml of an additive solution, such as SAGM - saline,  
658 adenine, glucose, and mannitol, and stored in a refrigerator<sup>90</sup>. This is could useful when feline blood  
659 components are not readily available from a commercial blood blank.

660

### 661 **Practical blood administration**

662 Blood products are usually given intravenously via a peripheral vein, but occasionally via a central  
663 vein or via an intraosseous route in small patients. A dedicated intravenous line should be used.

664

665 Blood products should not be administered with intravenous fluids containing calcium or glucose  
666 supplementation (e.g. Hartmann's, lactated Ringer's). Calcium overwhelms the chelating ability of  
667 the citrate anticoagulant in stored blood and increases risk of clot formation. Appropriate fluid  
668 choices would be 0.9% saline or Plasmalyte.

669

670 Blood products must be administered using an appropriate filter to reduce red cell aggregates and  
671 microthrombi entering the recipient's circulation. Filters in standard fluid therapy administration  
672 sets are too small and blood will clot if administered through them. Use of a syringe and  
673 microaggregate filter system does not appear to damage transfused RBCs<sup>91</sup>. Gravity administration  
674 using a standard blood giving set can be used but control of administration rate is more difficult.  
675 Ideally, a syringe and syringe driver with an inline microaggregate filter system (e.g. Hemo-Nate 18  
676 µm filter, IMS, UK) is best. In most centres the filter is placed in the administration line as close to  
677 the patient as possible (Figure 9). Some authors will filter the blood as it is removed from the bag  
678 into a syringe, prior to administration to the patient. Either is an appropriate method for removing  
679 microthrombi from the FWB or pRBCs.

680

### 681 **Transfusion volume and rate**

682 The volume of blood product administered to a patient can be calculated with various formulae,  
683 with the following formula performing best in one study, although formulas frequently fail to  
684 accurately predict post-transfusion recipient PCV<sup>92</sup>.

685 **PCV% increase = volume of blood transfused in ml/ (2 x bodyweight in kg)**

686 Practically, administration volume is rounded to the nearest unit (40-60 ml whole blood) unless the  
687 recipient is very small in which case a half unit or 10 ml/kg may be administered.

688

689 The rate of administration of the transfusion is determined by the condition of the patient. Patients  
690 with severe clinical signs associated with anaemia (e.g. weakness, tachycardia, tachypnoea,  
691 hyperdynamic or weak pulses, hypotension, dull mentation) may require blood products faster i.e.  
692 as a bolus or over 1-2 hours. Alternatively, as cats with severe or chronic anaemia may have signs of  
693 left heart overload<sup>93</sup>, transfusions may need to be given over a longer period (e.g. 4-6 hours) to  
694 reduce the risk of transfusion associated circulatory overload. However, recent work described a  
695 lack of transfusion-associated circulatory overload in anaemic cats and dogs receiving transfusions  
696<sup>94</sup>, suggesting that such an adjustment may not be required routinely, although it is still a risk in  
697 patients with underlying cardiac disease, for example, and so close monitoring is indicated. If blood  
698 products are kept at room temperature for more than 4 hours there is a greater risk of bacterial  
699 contamination, which should also be considered when calculating administration rates.

700

701 **BOX OUT START**

702 **Rate of transfusion administration**

703 In patients not requiring rapid volume replacement, transfused blood should be administered at 0.5  
704 ml/kg/hour for the first 30 minutes and the patient monitored constantly for signs of a transfusion  
705 reaction (see below) such as vocalization, tachycardia, hypersalivation, vomiting, diarrhoea, facial  
706 swelling/urticaria, piloerection, or tachypnoea/respiratory distress. After this time, the rate may be  
707 increased to 1 ml/kg/hr for 30 minutes. If there is still no evidence of a transfusion reaction, the  
708 administration rate is increased so the total transfusion volume remaining is administered within a  
709 4-hour period, although some follow the 1 ml/kg/hr rate with a period of 20 minutes at 2 ml/kg/hr  
710 before increasing the rate further.

711 **BOX OUT END**



712

713 **Monitoring the recipient**

714 Patients must be monitored very closely whenever receiving a blood transfusion, particularly within  
715 the first 30 minutes of administration as this is the most common time for a severe transfusion  
716 reaction to develop. A baseline check of vital signs is performed before commencing the  
717 transfusion, including temperature, heart rate, pulse quality, blood pressure, mucous membrane  
718 colour, respiratory rate/effort, oxygen saturation and patient mentation.

719

720 These parameters are checked very frequently (initially every five minutes) for the first 30-60  
721 minutes (Figure 10a and Figure 10b). Depending on the clinical status of the patient, a  
722 multiparameter machine may be used to allow continuous monitoring of heart rate,  
723 electrocardiogram, SpO<sub>2</sub>, blood pressure and temperature throughout the transfusion. Assessment  
724 of vital parameter data trends (e.g. gradual increase in heart rate, respiratory rate, temperature) is  
725 key to early identification of a transfusion reaction and ensuring detailed records are kept  
726 throughout the transfusion is extremely important (Table 3).

727

728 Table 3: An example of a blood product administration sheet used for monitoring cats to help allow  
729 for early detection of any problems. T = temperature. P = pulse rate. R = respiration rate. BP = blood  
730 pressure. MMemb = mucous membrane. PCV = packed cell volume.

731

## Example Blood Product Administration Sheet for Cats

732 Date .....

733 Weight ..... kg Vet .....

734 Blood type .....

735 Donor reference .....

736 Cross-matched? Y  N 

Patient Sticker

737 Blood product (*likely whole blood*)

738 ..... Unit size ..... mls

739 **Dose estimation:  $\approx$ 1% increase in PCV is seen for every 2ml/kg of whole blood**

Time	Rate	Volume given (mls)	Actual Rate Given	Monitoring – see below
<b>Start</b> .....	<b>0.5 ml/kg/hr</b> for 1 <sup>st</sup> 30 mins	Volume =	.....ml/hr	T, P, R, BP Q 15 mins for 1 <sup>st</sup> hour & then at end; can do this more frequently if any concerns
	<b>1.0 ml/kg/hr</b> for next 30 mins	Volume =	.....ml/hr	
<b>Finish</b> .....	As prescribed – <i>but should not really exceed 10 ml/kg/hr</i>	<b>Remainder of unit volume given over 4 hours</b> Volume =	.....ml/hr	

740

**Complete the transfusion within 4 hours**

	Time	T (°C)	Pulse rate & quality	MMemb colour & CRT	RR & pattern	BP (mmHg)	PCV %	Comments
<b>Start</b>								
<b>15mins</b>								
<b>30mins</b>								
<b>45mins</b>								
<b>1 hour</b>								
<b>Optional time points</b>								
<b>End</b>								

741

742 Total volume given (mls) \_\_\_\_\_

743 Any transfusion reactions?

744 \_\_\_\_\_

745 \_\_\_\_\_

746 \_\_\_\_\_

747 Please record any notes and further checks on the patient's sheet

748 **Signs of a transfusion reaction** include pyrexia, restlessness, vomiting, salivation, change in  
749 RR and/or pattern (dyspnoea), change in HR and/or rhythm, change in BP, weak pulses,  
750 vocalization, diarrhoea, urticaria.

751 If any reaction is seen, **the transfusion should be stopped immediately**, and the **vet**  
752 **contacted**. The volume infused, and rate of infusion is recorded (do not discard the blood,  
753 line or fluids). Other considerations may be required under vet guidance:

- 754 ▪ Start cardiopulmonary resuscitation (CPR) if necessary
- 755 ▪ Examine the unit for haemolysis by spinning a microhaematocrit tube containing a  
756 sample of the donor blood and look for haemoglobinaemia
- 757 ▪ Examine the recipient for haemolysis by spinning a microhaematocrit tube of blood from  
758 the recipient and look for haemoglobinaemia
- 759 ▪ Consider starting IVF therapy (e.g. crystalloid bolus at 10 ml/kg) – this may be required  
760 to avoid renal damage if severe intravascular haemolysis or if signs of shock are present  
761 (hypotension, pallor, tachycardia/bradycardia)
- 762 ▪ Consider treatment with adrenaline (10-20 µg/kg of a 1: 10,000 solution (100 µg (0.1 mg)  
763 per ml) IV or IM) and antihistamines (e.g. diphenhydramine 1 mg/kg IV or IM)
- 764 ▪ If volume overload has resulted in pulmonary oedema, diuretic treatment and oxygen  
765 support may be required – chest imaging and/or echocardiography may be indicated
- 766 ▪ Culture (or e.g. PCR) of a sample of the donor unit may be required if infection or  
767 contamination is suspected, but bacterial contamination is unlikely in fresh well-handled  
768 blood
- 769 ▪ Antipyretics (e.g. meloxicam) may be required in some cases (renal function must be ok)

770 **Transfusion Reactions**

771 Despite appropriate screening, transfusion reactions in cats remain unpredictable and can vary in  
772 severity. Transfusion reactions can be defined as acute or delayed (see Table 4). The most common  
773 transfusion reactions seen in cats include febrile non-haemolytic transfusion reactions, allergic  
774 reactions and transfusion-associated circulatory overload. Transfusion reactions may cause immune-  
775 mediated haemolysis, which can result in jaundice, pigmenturia and/or pyrexia, mainly due to anti-  
776 blood type reactions. Transfusion reactions can also cause non-haemolytic reactions e.g. transient  
777 increases in body temperature, facial pruritis, facial swelling (Figure 11), vomiting and salivation.  
778 Increased vocalisation or agitation can often be a preceding sign to a non-haemolytic reaction.  
779

780 Table 4: Association of Veterinary Haematology and Transfusion Medicine (AVHTM) Consensus  
781 Working Group definitions of transfusion reactions (reproduced with permission from AVHTM <sup>95</sup>).

<b>ACUTE TRANSFUSION REACTION DEFINITIONS</b>	
<b>Acute Haemolytic Transfusion Reaction (AHTR)</b>	Acute, non-infectious, immunologic, or non-immunologic reaction that occurs secondary to accelerated destruction of transfused or recipient RBCs and is characterized by acute haemolysis. Acute haemolytic transfusion reactions occur during or within 24 hours of blood product administration. Causes of AHTRs can be divided into blood type incompatibilities and other causes of damage to transfused blood cells. Blood type incompatibilities are immunologic acute haemolytic reactions that are type II hypersensitivity reactions due to major or minor incompatibilities between donor and recipient RBCs. A classic example would be in the case of a type A unit of blood given to a type B cat. Non-

	immunologic causes of AHTRs may include thermal, osmotic, mechanical, or chemical factors that damage transfused blood cells.
<b>Allergic Reaction</b>	Acute immunologic reaction that is secondary to a type I hypersensitivity response to an antigen within a blood product. This reaction occurs during or within 4 hours of transfusion. It is characterized by clinical signs varying from transient and self-limiting to life-threatening anaphylaxis. Feline type I hypersensitivity reactions are typically respiratory (due to upper respiratory tract oedema, bronchoconstriction, and excessive mucus production) although gastrointestinal signs and severe pruritus can also occur.
<b>Febrile Non-Haemolytic Transfusion Reaction (FNHTR)</b>	Acute non-immunologic or immunologic reaction characterized by a temperature > 39°C (102.5°F) AND an increase in temperature of > 1°C (1.8°F) from the pre-transfusion body temperature during or within 4 hours of the end of a transfusion where external warming, underlying patient infection, AHTR, TRALI, and TTI have been ruled out.
<b>Transfusion Associated Circulatory Overload (TACO)</b>	Acute, non-immunologic reaction that is secondary to an increase in blood volume mediated by blood transfusion, characterized by acute respiratory distress and hydrostatic pulmonary oedema. This reaction occurs during or within 6 hours of transfusion. It is associated with clinical, echocardiographic, radiographic, or laboratory evidence of left atrial hypertension or volume overload. These patients typically have a positive response to diuretic therapy.

<p><b>Transfusion Associated Lung Injury (TRALI)</b></p>	<p>Acute, immunologic reaction that is secondary to antigen-antibody interactions in the lungs. TRALI is characterized by acute hypoxemia with evidence of non-cardiogenic pulmonary oedema on thoracic radiographs, during or within six hours of allogenic blood transfusion. Patients diagnosed with TRALI have no prior lung injury, no evidence of left atrial hypertension and no temporal relationship to an alternative risk factor for ARDS.</p>
<p><b>Transfusion Associated Dyspnoea (TAD)</b></p>	<p>Acute transfusion reaction characterized by the development of acute respiratory distress during or within 24 hours of the end of a transfusion where TACO, TRALI, allergic reaction, and underlying pulmonary disease have been ruled out.</p>
<p><b>Hypotensive Transfusion Reaction</b></p>	<p>Acute, non-immunologic reaction that is secondary to the infusion of stimulators of vasodilation and hypotension. It is characterized by the rapid onset of significant hypotension during or shortly after the completion of a transfusion, with the absence of other causes of hypotension, and improvement with cessation of the infusion. There is usually a decrease in systolic blood pressure of at least 30 mmHg from baseline.</p>
<p><b>Citrate Toxicity</b></p>	<p>Acute, non-immunologic reaction that is secondary to the transfusion of a large volume of blood, with citrate as the anticoagulant, and is characterized by a significant systemic hypocalcaemia within hours of initiating transfusion.</p>

<b>Hyperammonaemia</b>	Acute, non-immunologic reaction that is secondary to hyperammonaemia and characterized by signs of development of encephalopathy (neurologic signs as ataxia, head pressing, circling, seizures and vomiting), during or immediately after (minutes to few hours) blood transfusion of stored blood or stored blood components. It is a potentially life-threatening reaction in patients with liver disease (liver failure, portosystemic shunt, premature neonates with immature functioning liver) who are unable to metabolize and excrete ammonia properly.
<b>ACUTE-TO-DELAYED TRANSFUSION REACTION DEFINITIONS</b>	
<b>Transfusion Transmitted Infection (TTI)</b>	Acute or delayed, non-immunologic reaction secondary to the transfusion of pathogen contaminated blood or blood components. A TTI can occur hours to years after the transfusion due to the presence of the infectious agent in the blood/blood component unit collected from an infected donor, or from pathogen contamination of blood/blood component units during processing, storage or transfusion. Clinical signs are highly dependent on pathogen transmitted and its pathogenicity for dogs and cats and the clinical status of the recipient.
<b>Transfusion-associated graft vs. host disease (TAGVHD)</b>	Acute to delayed immunologic reaction that is secondary to donor lymphocytes engrafting on and eventually attacking host tissue. TAGVHD occurs 48 hours to 6 weeks following transfusion and has a high mortality rate in human patients (>90%). The reaction is characterized by a skin rash, diarrhea, fever, hepatic dysfunction, and bone marrow hypoplasia. Liver and skin histopathology have a characteristic appearance. In humans, it is

	most common in immunocompromised individuals or when special circumstances cause transient immunosuppression.
<b>DELAYED TRANSFUSION REACTION DEFINITIONS</b>	
<b>Delayed Haemolytic Transfusion Reaction (DHTR)</b>	Delayed, non-infectious, immunologic or non-immunologic, reaction that occurs secondary to lysis or accelerated clearance of transfused RBCs. Delayed haemolytic transfusion reactions occur 24 hours to 28 days after blood product administration. Immunologic DHTRs are typically caused by a secondary immune response to the donor's RBCs. Non-immunologic HTRs occur due to thermal, osmotic, mechanical, or chemical factors that damage transfused blood cells, causing delayed haemolysis.
<b>Delayed Serologic Transfusion Reaction (DSTR)</b>	Delayed, immunologic reaction that is secondary to the development of new clinically significant antibodies against the transfused product without evidence of haemolysis. DSTRs occur 24 hours to 28 days after a transfusion <sup>24</sup> .
<b>Post-Transfusion Purpura (PTP)</b>	Delayed, immunologic reaction that is secondary to alloimmunization against platelet antigens. It is characterized by thrombocytopenia arising 5-12 days following transfusion of any platelet-containing blood product.

782

783 In a group of 126 cats receiving blood transfusions, non-haemolytic reactions (7.9%) were more  
784 common than haemolytic reactions (0.8%) <sup>96</sup>. In another study of 91 cats, a transfusion reaction was  
785 only noted in 1.2% <sup>57</sup>.

786

787 The risk of a transfusion reaction increases with subsequent transfusions (typically from 2 days after  
788 an initial transfusion) <sup>24</sup>. Appropriate record keeping is essential so that subsequent veterinarians are



789 aware that the patient has received a blood transfusion. However, in 27 cats that received multiple  
790 blood transfusions, transfusion reactions remained uncommon<sup>97</sup>.

791

792 Should the patient develop mild signs of a transfusion reaction (e.g. mild 1-2°C increase in  
793 temperature or one episode of vomiting) then the transfusion rate should be reduced. If marked  
794 clinical signs develop the transfusion should be stopped and blood replaced with a crystalloid  
795 solution. Monitoring of the patient should be continued for evidence of shock (temperature, pulse  
796 rate, mucous membrane colour and systolic blood pressure). Serum and urine should be assessed  
797 for haemolysis and haemoglobinuria with sample centrifugation (Table 3) to look for evidence of  
798 haemolysis of the transfused red cells (e.g. red discolouration of serum or urine).

799

800 In the event of a severe transfusion reaction, the transfusion should be discontinued, and the  
801 patient assessed. If signs of shock (hypotension, pallor, tachycardia/bradycardia) a crystalloid fluid  
802 bolus (10 ml/kg) and adrenaline (10-20 µg/kg of a 1: 10,000 solution (100 µg (0.1 mg) per ml) IV or  
803 IM) should be administered and can be followed by a continuous rate infusion (CRI) of adrenaline.  
804 Antihistamines (e.g. diphenhydramine 1 mg/kg IV or IM) and corticosteroids (e.g. hydrocortisone 2-  
805 4mg/kg IV or IM or dexamethasone 0.05-0.1mg/kg IM or IV) may also be considered, although  
806 evidence for use of corticosteroids in acute transfusion reactions is limited and patient  
807 contraindications and potential adverse effects should be taken into account. The donor blood  
808 sample/unit should be assessed by checking a PCV for evidence of haemolysis and potentially  
809 submitting a sample for bacterial culture.

810

811 Cats may develop signs of volume overload following transfusion. This is of particular concern in  
812 patients with cardiac disease, normovolaemic to hypervolaemic anaemic patients (e.g. immune-  
813 mediated haemolytic anaemia), and chronically or severely anaemic patients although, as  
814 mentioned above, this alone may be less of a clinical concern<sup>94</sup>. If patients become tachypnoeic

815 following a transfusion, or develop a serous nasal discharge or conjunctival oedema, thoracic  
816 radiographs or thoracic ultrasound should be performed to evaluate for pleural effusion or  
817 pulmonary oedema. If pleural effusion is present, thoracocentesis should be performed. If  
818 pulmonary oedema is present, furosemide 1-2mg/kg IV every two hours as required (based on  
819 respiratory auscultation, respiratory rate and response) and oxygen therapy should also be  
820 instigated.

821

### 822 **Autologous blood transfusion**

823 Autologous blood transfusion (autotransfusion) is the administration of a patient's own blood as a  
824 transfusion. This can be considered in patients with haemothorax or haemoperitoneum. Cross-  
825 matching or blood typing is not required. Blood is collected in a sterile fashion using a 23G butterfly  
826 needle and 10 or 20 ml syringes. Administration of the collected blood is otherwise similar to  
827 standard donor-recipient transfusions. There is no clear evidence regarding whether anticoagulant  
828 should be added to the transfusion. Blood in contact with the peritoneal surface is reported to  
829 become defibrinated within one hour and anticoagulant administration may be unnecessary or lead  
830 to hypocalcaemia. The use of a blood filter (18 µm) is strongly recommended to prevent platelet and  
831 leukocyte passage. A recent report of eight cats with haemoperitoneum receiving autologous  
832 transfusion did not identify any adverse reactions<sup>98</sup>.

833

### 834 **Conclusion**

835 Feline blood donation and transfusion can be performed safely and effectively in veterinary practice,  
836 but the decision to do so must be made carefully. Donor and recipient cats should be blood typed,  
837 and ideally cross-matched if possible, prior to transfusion to avoid severe transfusion reactions. The  
838 decision to administer a transfusion is based on the potential recipient's clinical condition and cause  
839 of anaemia rather than PCV alone. Donors should be assessed for health, temperament and  
840 infectious agents and, in most cases, sedated appropriately for blood collection. Blood can be

841 collected using an open or closed system and recipients should be monitored for signs of a  
842 transfusion reaction. Xenotransfusion may be given only once, allowing for short-term stabilisation  
843 of the recipient but destruction of donated RBCs occurs after a short time.

844

## 845 **References**

- 846 1. Barfield D and Adamantos S. Feline blood transfusions: A pinker shade of pale. *J Feline Med*  
847 *Surg.* 2011; 13: 11-23.
- 848 2. Davidow B. Transfusion medicine in small animals. *Vet Clin North Am Small Anim Pract.*  
849 2013; 43: 735-756.
- 850 3. Forcada Y, Guitian J and Gibson G. Frequencies of feline blood types at a referral hospital in  
851 the south east of England. *J Small Anim Pract.* 2007; 48: 570-573.
- 852 4. Malik R, Griffin DL, White JD, et al. The prevalence of feline A/B blood types in the Sydney  
853 region. *Aust Vet J.* 2005; 83: 38-44.
- 854 5. Knottenbelt CM, Addie DD, Day MJ and Mackin AJ. Determination of the prevalence of feline  
855 blood types in the UK. *J Small Anim Pract.* 1999; 40: 115-118.
- 856 6. Gunn-Moore DA, Simpson KE and Day MJ. Blood types in Bengal cats in the UK. *J Feline Med*  
857 *Surg.* 2009; 11: 826-828.
- 858 7. Jensen AL, Olesen AB and Arnbjerg J. Distribution of feline blood types detected in the  
859 Copenhagen area of Denmark. *Acta Vet Scand.* 1994; 35: 121-124.
- 860 8. Cattin RP. Distribution of blood types in a sample of 245 New Zealand non-purebred cats. *N*  
861 *Z Vet J.* 2016; 64: 154-157.
- 862 9. Nectoux A, Guidetti M, Barthelemy A, Pouzot-Nevoret C, Hoareau GL and Goy-Thollot I.  
863 Assessment of risks of feline mismatched transfusion and neonatal isoerythrolysis in the Lyon  
864 (France) area. *JFMS Open Rep.* 2019; 5: 2055116919863175.
- 865 10. Di Tommaso M, Miglio A, Crisi PE, et al. Frequency of Blood Types A, B and AB in a  
866 Population of Non-Pedigree Domestic Cats from Central Italy. *Animals (Basel).* 2020; 10.

- 867 11. Spada E, Perego R, Baggiani L, et al. Prevalence of Blood Types and Alloantibodies of the AB  
868 Blood Group System in Non-Pedigree Cats from Northern (Lombardy) and Southern (Sicily) Italy.  
869 *Animals (Basel)*. 2020; 10.
- 870 12. Proverbio D, Spada E, Perego R, Della Pepa A, Bagnagatti De Giorgi G and Baggiani L.  
871 Assessment of blood types of Ragdoll cats for transfusion purposes. *Vet Clin Pathol*. 2013; 42: 157-  
872 162.
- 873 13. Knottenbelt CM, Day MJ, Cripps PJ and Mackin AJ. Measurement of titres of naturally  
874 occurring alloantibodies against feline blood group antigens in the UK. *J Small Anim Pract*. 1999; 40:  
875 365-370.
- 876 14. Bucheler J and Giger U. Alloantibodies against a and B Blood Types in Cats. *Vet Immunol*  
877 *Immunopathol*. 1993; 38: 283-295.
- 878 15. Axner E. A questionnaire on survival of kittens depending on the blood groups of the  
879 parents. *J Feline Med Surg*. 2014; 16: 781-787.
- 880 16. Cain GR and Suzuki Y. Presumptive neonatal isoerythrolysis in cats. *J Am Vet Med Assoc*.  
881 1985; 187: 46-48.
- 882 17. Rudd S. Feline blood types and blood typing methods. In: Harvey AM and Tasker S, (eds.).  
883 *BSAVA Manual of Feline Practice A Foundation Manual*. Gloucester: British Small Animal Veterinary  
884 Association, 2013, p. 454-456.
- 885 18. Seth M, Jackson KV and Giger U. Comparison of five blood-typing methods for the feline AB  
886 blood group system. *Am J Vet Res*. 2011; 72: 203-209.
- 887 19. Hourani L, Weingart C and Kohn B. Evaluation of a novel feline AB blood typing device. *J*  
888 *Feline Med Surg*. 2014; 16: 826-831.
- 889 20. Spada E, Proverbio D, Baggiani L, Bagnagatti De Giorgi G, Perego R and Ferro E. Evaluation of  
890 an immunochromatographic test for feline AB system blood typing. *J Vet Emerg Crit Care (San*  
891 *Antonio)*. 2016; 26: 137-141.

- 892 21. Goy-Thollot I, Nectoux A, Guidetti M, et al. Detection of naturally occurring alloantibody by  
893 an in-clinic antiglobulin-enhanced and standard crossmatch gel column test in non-transfused  
894 domestic shorthair cats. *J Vet Intern Med.* 2019; 33: 588-595.
- 895 22. Weinstein NM, Blais MC, Harris K, Oakley DA, Aronson LR and Giger U. A newly recognized  
896 blood group in domestic shorthair cats: the Mik red cell antigen. *J Vet Intern Med.* 2007; 21: 287-  
897 292.
- 898 23. Tasker S, Barker EN, Day MJ and Helps CR. Feline blood genotyping versus phenotyping, and  
899 detection of non-AB blood type incompatibilities in UK cats. *J Small Anim Pract.* 2014; 55: 185-189.
- 900 24. Hourani L, Weingart C and Kohn B. Alloimmunisation in transfused patients: serial cross-  
901 matching in a population of hospitalised cats. *J Feline Med Surg.* 2017; 19: 1231-1237.
- 902 25. McClosky ME, Cimino Brown D, Weinstein NM, et al. Prevalence of naturally occurring non-  
903 AB blood type incompatibilities in cats and influence of crossmatch on transfusion outcomes. *J Vet*  
904 *Intern Med.* 2018; 32: 1934-1942.
- 905 26. Sylvane B, Prittie J, Hohenhaus AE and Tozier E. Effect of cross-match on packed cell volume  
906 after transfusion of packed red blood cells in transfusion-naive anemic cats. *J Vet Intern Med.* 2018;  
907 32: 1077-1083.
- 908 27. Binvel M, Arsenault J, Depre B and Blais MC. Identification of 5 novel feline erythrocyte  
909 antigens based on the presence of naturally occurring alloantibodies. *J Vet Intern Med.* 2021; 35:  
910 234-244.
- 911 28. Humm KR and Chan DL. Prospective evaluation of the utility of cross-matching prior to first  
912 transfusion in cats: 101 cases. *J Small Anim Pract.* 2020; 61: 285-291.
- 913 29. Martinez-Sogues L, Blois SL, Manzanilla EG, Abrams-Ogg AO and Cosentino P. Exploration of  
914 risk factors for non-survival and for transfusion-associated complications in cats receiving red cell  
915 transfusions: 450 cases (2009 to 2017). *J Small Anim Pract.* 2020; 61: 177-184.
- 916 30. Safrany B and Adamantos S. Is a cross-match necessary before a cat's first blood  
917 transfusion? *Vet Evidence.* 2020; 5.

- 918 31. Poh D, Claus M, Smart L and Sharp C. Transfusion practice in Australia: an internet-based  
919 survey. *Aust Vet J.* 2021; doi: 10.1111/avj.13049.
- 920 32. Vap LM, Harr KE, Arnold JE, et al. ASVCP quality assurance guidelines: control of  
921 preanalytical and analytical factors for hematology for mammalian and nonmammalian species,  
922 hemostasis, and crossmatching in veterinary laboratories. *Vet Clin Pathol.* 2012; 41: 8-17.
- 923 33. Pennisi MG and members. a. ABCD Guidelines on Blood transfusion in cats.  
924 <http://www.abcdcatsvets.org/blood-transfusion-in-cats/>. 2020; Accessed 13th February 2021.
- 925 34. Wardrop KJ, Birkenheuer A, Blais MC, et al. Update on Canine and Feline Blood Donor  
926 Screening for Blood-Borne Pathogens. *J Vet Intern Med.* 2016; 30: 15-35.
- 927 35. Gary AT, Richmond HL, Tasker S, Hackett TB and Lappin MR. Survival of *Mycoplasma*  
928 *haemofelis* and '*Candidatus Mycoplasma haemominutum*' in blood of cats used for transfusions. *J*  
929 *Feline Med Surg.* 2006; 8: 321-326.
- 930 36. Barker EN. Update on Feline Hemoplasmosis. *Vet Clin North Am Small Anim Pract.* 2019; 49:  
931 733-743.
- 932 37. Alvarez-Fernandez A, Breitschwerdt EB and Solano-Gallego L. Bartonella infections in cats  
933 and dogs including zoonotic aspects. *Parasit Vectors.* 2018; 11: 624.
- 934 38. Bradbury CA, Green M, Brewer M, Breitschwerdt E and Lappin M. Survival of Bartonella  
935 henselae in the blood of cats used for transfusion. *J Vet Intern Med (abstract).* 2010; 24: 759.
- 936 39. Kordick DL and Breitschwerdt EB. Relapsing bacteremia after blood transmission of  
937 Bartonella henselae to cats. *Am J Vet Res.* 1997; 58: 492-497.
- 938 40. Hartmann K. Clinical aspects of feline retroviruses: a review. *Viruses.* 2012; 4: 2684-2710.
- 939 41. Nesina S, Helfer-Hungerbuehler AK, Riond B, et al. Retroviral DNA-the silent winner: blood  
940 transfusion containing latent feline leukemia provirus causes infection and disease in naive recipient  
941 cats. *Retrovirology.* 2015; 12.
- 942 42. Little S, Levy J, Hartmann K, et al. 2020 AAFP Feline Retrovirus Testing and Management  
943 Guidelines. *J Feline Med Surg.* 2020; 22: 5-30.

- 944 43. Lappin MR, Tasker S and Roura X. Role of vector-borne pathogens in the development of  
945 fever in cats: 2. Tick- and sandfly-associated diseases. *J Feline Med Surg.* 2020; 22: 41-48.
- 946 44. Pennisi MG, Hofmann-Lehmann R, Radford AD, et al. Anaplasma, Ehrlichia and Rickettsia  
947 species infections in cats: European guidelines from the ABCD on prevention and management. *J*  
948 *Feline Med Surg.* 2017; 19: 542-548.
- 949 45. Lappin MR, Griffin B, Brunt J, et al. Prevalence of Bartonella species, haemoplasma species,  
950 Ehrlichia species, Anaplasma phagocytophilum, and Neorickettsia risticii DNA in the blood of cats  
951 and their fleas in the United States. *J Feline Med Surg.* 2006; 8: 85-90.
- 952 46. Nentwig A, Meli ML, Schrack J, et al. First report of Cytauxzoon sp. infection in domestic cats  
953 in Switzerland: natural and transfusion-transmitted infections. *Parasit Vectors.* 2018; 11: 292.
- 954 47. Hartmann K, ABCD Members and Penzhorn BL. ABCD Guidelines on Babesiosis in cats.  
955 <http://www.abcdcatsvetsorg/babesiosis/>. 2020; Accessed 13th February 2021.
- 956 48. Pennisi MG, Lloret A and Members. A. ABCD Guidelines on Cytauxzoonosis in cats.  
957 <http://www.abcdcatsvetsorg/cytauxzoonosis/>. 2020; Accessed 13th February 2021.
- 958 49. Meinkoth JH and Kocan AA. Feline cytauxzoonosis. *Vet Clin North Am Small Anim Pract.*  
959 2005; 35: 89-101, vi.
- 960 50. Paige CF, Abbott JA, Elvinger F and Pyle RL. Prevalence of cardiomyopathy in apparently  
961 healthy cats. *J Am Vet Med Assoc.* 2009; 234: 1398-1403.
- 962 51. Fox PR, Rush JE, Reynolds CA, et al. Multicenter evaluation of plasma N-terminal probrain  
963 natriuretic peptide (NT-pro BNP) as a biochemical screening test for asymptomatic (occult)  
964 cardiomyopathy in cats. *J Vet Intern Med.* 2011; 25: 1010-1016.
- 965 52. Winzelberg Olson S and Hohenhaus AE. Feline non-regenerative anemia: Diagnostic and  
966 treatment recommendations. *J Feline Med Surg.* 2019; 21: 615-631.
- 967 53. Balakrishnan A, Drobatz KJ and Reineke EL. Development of anemia, phlebotomy practices,  
968 and blood transfusion requirements in 45 critically ill cats (2009-2011). *J Vet Emerg Crit Car.* 2016;  
969 26: 406-411.

- 970 54. Lane WG and Sinnott-Stutzman VB. Retrospective evaluation of fresh frozen plasma use in  
971 121 cats: 2009-2016. *J Vet Emerg Crit Car.* 2020; 30: 558-566.
- 972 55. Mansi ET, Waldrop JE and Davidow EB. Retrospective evaluation of the indications, safety  
973 and effects of fresh frozen plasma transfusions in 36 cats (2014-2018). *J Feline Med Surg.* 2020; 22:  
974 696-704.
- 975 56. Kohn B, Weingart C and Giger U. Haemorrhage in seven cats with suspected anticoagulant  
976 rodenticide intoxication. *J Feline Med Surg.* 2003; 5: 295-304.
- 977 57. Weingart C, Giger U and Kohn B. Whole blood transfusions in 91 cats: a clinical evaluation. *J*  
978 *Feline Med Surg.* 2004; 6: 139-148.
- 979 58. Bebar KN, Sinnott V and Brooks MB. Recurrent hemorrhage caused by type 3 von Willebrand  
980 disease in a domestic long-haired cat. *J Vet Emerg Crit Car.* 2014; 24: 326-331.
- 981 59. French TW, Fox LE, Randolph JF and Dodds WJ. A bleeding disorder (von Willebrand's  
982 disease) in a Himalayan cat. *J Am Vet Med Assoc.* 1987; 190: 437-439.
- 983 60. Maggio-Price L and Dodds WJ. Factor IX deficiency (hemophilia B) in a family of British  
984 shorthair cats. *J Am Vet Med Assoc.* 1993; 203: 1702-1704.
- 985 61. Cotter SM, Brenner RM and Dodds WJ. Hemophilia A in three unrelated cats. *J Am Vet Med*  
986 *Assoc.* 1978; 172: 166-168.
- 987 62. Snow SJ, Ari Jutkowitz L and Brown AJ. Trends in plasma transfusion at a veterinary teaching  
988 hospital: 308 patients (1996-1998 and 2006-2008). *J Vet Emerg Crit Car.* 2010; 20: 441-445.
- 989 63. Wondratschek C, Weingart C and Kohn B. Primary immune-mediated thrombocytopenia in  
990 cats. *J Am Anim Hosp Assoc.* 2010; 46: 12-19.
- 991 64. Callan MB, Griot-Wenk ME, Hackner SG and Giger U. Persistent thrombopathy causing  
992 bleeding in 2 domestic shorthaired cats. *J Vet Intern Med.* 2000; 14: 217-220.
- 993 65. Bovens C and Gruffydd-Jones T. Xenotransfusion with canine blood in the feline species:  
994 review of the literature. *J Feline Med Surg.* 2013; 15: 62-67.



- 995 66. Oron L, Bruchim Y, Klainbart S and Kelmer E. Ultrasound-guided intracardiac xenotransfusion  
996 of canine packed red blood cells and epinephrine to the left ventricle of a severely anemic cat during  
997 cardiopulmonary resuscitation. *J Vet Emerg Crit Car.* 2017; 27: 218-223.
- 998 67. Euler CC, Raj K, Mizukami K, et al. Xenotransfusion of anemic cats with blood compatibility  
999 issues: pre- and posttransfusion laboratory diagnostic and crossmatching studies. *Vet Clin Pathol.*  
1000 2016; 45: 244-253.
- 1001 68. Le Gal A, Thomas EK and Humm KR. Xenotransfusion of canine blood to cats: a review of 49  
1002 cases and their outcome. *J Small Anim Pract.* 2019.
- 1003 69. Marion RS and Smith JE. Survival of erythrocytes after autologous and allogeneic transfusion  
1004 in cats. *J Am Vet Med Assoc.* 1983; 183: 1437-1439.
- 1005 70. Doolin KS, Chan DL, Adamantos S and Humm K. Retrospective evaluation of unexpected  
1006 events during collection of blood donations performed with and without sedation in cats (2010-  
1007 2013). *J Vet Emerg Crit Car.* 2017; 27: 555-560.
- 1008 71. Rand JS, Kinnaird E, Baglioni A, Blackshaw J and Priest J. Acute stress hyperglycemia in cats is  
1009 associated with struggling and increased concentrations of lactate and norepinephrine. *J Vet Intern*  
1010 *Med.* 2002; 16: 123-132.
- 1011 72. Reader RC, Barton BA and Abelson AL. Comparison of two intramuscular sedation protocols  
1012 on sedation, recovery and ease of venipuncture for cats undergoing blood donation. *J Feline Med*  
1013 *Surg.* 2019; 21: 95-102.
- 1014 73. Reynolds BS, Geffre A, Bourges-Abella NH, et al. Effects of intravenous, low-dose ketamine-  
1015 diazepam sedation on the results of hematologic, plasma biochemical, and coagulation analyses in  
1016 cats. *J Am Vet Med Assoc.* 2012; 240: 287-293.
- 1017 74. Troyer HL, Feeman WE, Gray TL and Couto CG. Comparing chemical restraint and  
1018 anesthetic protocols used for blood donation in cats: one teaching hospital's experience. *Vet Med.*  
1019 2005; 100: 652-658.

- 1020 75. Killos MB, Graham LF and Lee J. Comparison of two anesthetic protocols for feline blood  
1021 donation. *Vet Anaesth Analg.* 2010; 37: 230-239.
- 1022 76. Dhumeaux MP, Snead EC, Epp TY, et al. Effects of a standardized anesthetic protocol on  
1023 hematologic variables in healthy cats. *J Feline Med Surg.* 2012; 14: 701-705.
- 1024 77. Biermann K, Hungerbuhler S, Mischke R and Kastner SB. Sedative, cardiovascular,  
1025 haematologic and biochemical effects of four different drug combinations administered  
1026 intramuscularly in cats. *Vet Anaesth Analg.* 2012; 39: 137-150.
- 1027 78. Granfone MC, Walker JM and Smith LJ. Evaluation of an intramuscular butorphanol and  
1028 alfaxalone protocol for feline blood donation: a pilot study. *J Feline Med Surg.* 2018; 20: 793-798.
- 1029 79. Muir W, Lerche P, Wiese A, Nelson L, Pasloske K and Whitem T. The cardiorespiratory and  
1030 anesthetic effects of clinical and supraclinical doses of alfaxalone in cats. *Vet Anaesth Analg.* 2009;  
1031 36: 42-54.
- 1032 80. Spada E, Proverbio D, Bagnagatti De Giorgi G, et al. Clinical and haematological responses of  
1033 feline blood donors anaesthetised with a tiletamine and zolazepam combination. *J Feline Med Surg.*  
1034 2015; 17: 338-341.
- 1035 81. Iazbik MC, Gomez Ochoa P, Westendorf N, Charske J and Couto CG. Effects of blood  
1036 collection for transfusion on arterial blood pressure, heart rate, and PCV in cats. *J Vet Intern Med.*  
1037 2007; 21: 1181-1184.
- 1038 82. Cremer J and Ricco CH. Cardiovascular, respiratory and sedative effects of intramuscular  
1039 alfaxalone, butorphanol and dexmedetomidine compared with ketamine, butorphanol and  
1040 dexmedetomidine in healthy cats. *J Feline Med Surg.* 2018; 20: 973-979.
- 1041 83. Crestani C, Stefani A, Carminato A, et al. In vitro assessment of quality of citrate-phosphate-  
1042 dextrose-adenine-1 preserved feline blood collected by a commercial closed system. *J Vet Intern*  
1043 *Med.* 2018; 32: 1051-1059.
- 1044 84. Binvel M, Fairbrother JH, Levesque V and Blais MC. Comparison of a closed system and an  
1045 open system for blood collection in feline donors. *J Feline Med Surg.* 2020; 22: 1121-1128.

- 1046 85. Spada E, Perego R, Baggiani L, Martino PA and Proverbio D. Hematological, biochemical and  
1047 microbiological evaluation of feline whole blood units collected using an open system and stored for  
1048 35 days. *Vet J.* 2019; 254: 105396.
- 1049 86. Spada E, Proverbio D, Baggiani L, Bagnagatti De Giorgi G, Ferro E and Perego R. Change in  
1050 haematological and selected biochemical parameters measured in feline blood donors and feline  
1051 whole blood donated units. *J Feline Med Surg.* 2017; 19: 375-381.
- 1052 87. Rudd S. Blood transfusion. In: Harvey AM and Tasker S, (eds.). *BSAVA Manual of Feline*  
1053 *Practice A Foundation Manual.* Gloucester: British Small Animal Veterinary Association, 2013, p. 456-  
1054 460.
- 1055 88. FuturLab: The first closed system for blood collection and storage for cats.  
1056 <https://www.youtube.com/watch?v=fPFq8oGSwRk>. accessed 6th February 2021.
- 1057 89. Mansell CL and Boller M. Blood component processing and storage. I. In: Yagi K and  
1058 Holowaychuk MK, (eds.). *Manual of Veterinary Transfusion Medicine and Blood Banking.* Ames, IA:  
1059 Wiley Blackwell, 2016, p. 237-255.
- 1060 90. Spada E, Perego R, Baggiani L, Martino PA and Proverbio D. Evaluation of feline packed red  
1061 blood cell units obtained by blood sedimentation and stored for 42 days for transfusion purposes. *J*  
1062 *Vet Intern Med.* 2020; 34: 418.
- 1063 91. Heikes BW and Ruaux CG. Effect of syringe and aggregate filter administration on survival of  
1064 transfused autologous fresh feline red blood cells. *J Vet Emerg Crit Car.* 2014; 24: 162-167.
- 1065 92. Reed N, Espadas I, Lalor SM and Kisielewicz C. Assessment of five formulae to predict post-  
1066 transfusion packed cell volume in cats. *Journal of Feline Medicine and Surgery.* 2014; 16: 651-656.
- 1067 93. Wilson HE, Jasani S, Wagner TB, et al. Signs of left heart volume overload in severely  
1068 anaemic cats. *Journal of Feline Medicine and Surgery.* 2010; 12: 904-909.
- 1069 94. Donaldson RE, Seo J, Fuentes VL and Humm K. Left heart dimensions in anemic cats and  
1070 dogs before and after blood transfusion. *J Vet Intern Med.* 2020.

- 1071 95. Davidow B, Blois S, Goy-Thollot I, et al. Association of Veterinary Hematology and  
1072 Transfusion Medicine (AVHTM) Transfusion Reaction Small Animal Consensus Statement (TRACS).  
1073 Part One: Definitions and Clinical Signs. *J Vet Emerg Crit Care* doi:101111/vec13044. 2021 (in press).  
1074 96. Klaser DA, Reine NJ and Hohenhaus AE. Red blood cell transfusions in cats: 126 cases (1999).  
1075 *J Am Vet Med Assoc.* 2005; 226: 920-923.
- 1076 97. Roux FA, Deschamps JY, Blais MC, Welsh DM, Delaforcade-Buress AM and Rozanski EA.  
1077 Multiple red cell transfusions in 27 cats (2003-2006): indications, complications and outcomes. *J*  
1078 *Feline Med Surg.* 2008; 10: 213-218.
- 1079 98. Cole LP and Humm K. Twelve autologous blood transfusions in eight cats with  
1080 haemoperitoneum. *J Feline Med Surg.* 2019; 21: 481-487.